Global University Venturing

The Pittsburgh spinout is building a precision diagnostic platform that uses genomics to underpin research into conditions such as chronic pancreatic disease.

Neophore was launched by University of Cambridge biopharmaceutical developer PhoreMost in May 2017 to home in on potential immunotherapies for cancer.

Pennsylvania spinout Apellis Pharmaceuticals has floated on the Nasdaq Global Select Market after raising $150m in its initial public offering.

Graphcore, whose roots can be traced back to University of Bristol, has added $50m to its coffers thanks to a series C round backed by Bosch, Dell and Samsung.

Immunotherapy developer Arcus Biosciences, backed by Stanford University, has raised series C funding from a GV-led consortium that included Celgene and Taiho.

The cash will be used for a recruitment drive as QCI begins to ramp up the development of modules that could eventually be used for general purpose quantum computing.

EMBL-backed Arsanis hopes to sell 3,125,000 shares priced at $15 to $17 and raise a total of up to $61m in its initial public offering.

Atomic Mechanics has been spun out of Manchester to couple semiconductors with graphene to build highly reactive pressure sensors.

In all the companies we invest in, we try to build a cooperative mutually beneficial relationship

A summary of the Brazilian realm of corporate venture capital